Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2

International Journal of Molecular Sciences

Volumn 15, Issue 8, 2014, Pages 13637-13648

  Yang, Longhe ^a   Li, Yanting ^a   Ren, Jie ^a   Zhu, Chenggang ^a   Fu, Jin ^a   Lin, Donghai ^a   Qiu, Yan ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Cannabinoid receptors; Celastrol; Inflammatory pain; Neuropathic pain

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1, 3, 3 TRIMETHYLBICYCLO [2.2.1] HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 2 RECEPTOR; CARRAGEENAN; CELASTROL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANALGESIC AGENT; BORNANE DERIVATIVE; PYRAZOLE DERIVATIVE; TRIPTERINE; TRITERPENE;

ALLODYNIA; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; HYPERALGESIA; INFLAMMATORY PAIN; MOUSE; MRNA EXPRESSION ASSAY; NERVE INJURY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN ASSESSMENT; PAIN THRESHOLD; PAW EDEMA; PLETHYSMOGRAPHY; REAL TIME POLYMERASE CHAIN REACTION; STEREOMICROSCOPY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; EDEMA; GENETICS; METABOLISM; NEURALGIA; SIGNAL TRANSDUCTION; SPINAL CORD INJURIES; TRIPTERYGIUM;

ANALGESICS; ANIMALS; BORNANES; CARRAGEENAN; DISEASE MODELS, ANIMAL; EDEMA; HYPERALGESIA; INTERLEUKIN-1BETA; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; NEURALGIA; PYRAZOLES; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION; SPINAL CORD INJURIES; TRIPTERYGIUM; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925884782     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150813637     Document Type: Article

References (35)

1. Wong, K.F.; Yuan, Y.; Luk, J.M. Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents. Clin. Exp. Pharmacol. Physiol. 2012, 39, 311-320.
2. Kannaiyan, R.; Shanmugam, M.K.; Sethi, G. Molecular targets of celastrol derived from Thunder of God Vine: Potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 2011, 303, 9-20.
3. Nanjundaiah, S.M.; Venkatesha, S.H.; Yu, H.; Tong, L.; Stains, J.P.; Moudgil, K.D. Celastrus and its bioactive celastrol protect against bone damage in autoimmune arthitis by modulating osteoimmune cross-talk. J. Biol. Chem. 2012, 287, 22216-22226.
4. Venkatesha, S.H.; Yu, H.; Rajaiah, R.; Tong, L.; Moudgil, K.D. Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. J. Biol. Chem. 2011, 286, 15138-15146.
5. Gu, L.; Bai, W.; Li, S.; Zhang, Y.; Han, Y.; Gu, Y.; Meng, G.; Xie, L.; Wang, J.; Xiao, Y.; et al. Celastrol prevents atherosclerosis via inhibiting lox-1 and oxidative stress. PLoS One 2013, 8, e65477.
6. Paris, D.; Ganey, N.J.; Laporte, V.; Patel, N.S.; Beaulieu-Abdelahad, D.; Bachmeier, C.; March, A.; Ait-Ghezala, G.; Mullan, M.J. Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J. Neuroinflamm. 2010, 7, 17.
7. Allison, A.C.; Cacabelos, R.; Lombardi, V.R.; Alvarez, X.A.; Vigo, C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25, 1341-1357.
8. Kim, D.Y.; Park, J.W.; Jeoung, D.; Ro, J.Y. Celastrol suppresses allergen-induced airway inflammation in a mouse allergic asthma model. Eur. J. Pharmacol. 2009, 612, 98-105.
9. Xu, X.; Wu, Z.; Xu, C.; Ren, Y.; Ge, Y. Observation on serum anti-double stranded DNA antibodies of tripterine in systemic lupus erythematosus of (NZBxW)F1 mice. Ann. Rheum. Dis. 2003, 62, 377-378.
10. Piscitelli, F.; di Marzo, V. "Redundancy" of endocannabinoid inactivation: New challenges and opportunities for pain control. ACS Chem. Neurosci. 2012, 3, 356-363.
11. Pertwee, R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 2009, 156, 397-411.
12. Alvarez-Jaimes, L.J.; Palmer, J.A. The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation. Curr. Pharm. Biotechnol. 2011, 12, 1644-1659.
13. Iversen, L. Cannabis and the brain. Brain 2003, 126, 1252-1270.
14. Pertwee, R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 2001, 63, 569-611.
15. Moreira, F.A.; Grieb, M.; Lutz, B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: Focus on anxiety and depression. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23, 133-144.
16. Rice, A.S.; Farquhar-Smith, W.P.; Nagy, I. Endocannabinoids and pain: Spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot. Essent. Fat. Acids 2002, 66, 243-256.
17. Valenzano, K.J.; Tafesse, L.; Lee, G.; Harrison, J.E.; Boulet, J.M.; Gottshall, S.L.; Mark, L.; Pearson, M.S.; Miller, W.; Shan, S.; et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005, 48, 658-672.
18. Ibrahim, M.M.; Deng, H.; Zvonok, A.; Cockayne, D.A.; Kwan, J.; Mata, H.P.; Vanderah, T.W.; Lai, J.; Porreca, F.; Makriyannis, A.; et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. USA 2003, 100, 10529-10533.
19. Kerr, D.M.; Harhen, B.; Okine, B.N.; Egan, L.J.; Finn, D.P.; Roche, M. The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: Differential mechanisms of action. Br. J. Pharmacol. 2013, 169, 808-819.
20. Ghosh, S.; Wise, L.E.; Chen, Y.; Gujjar, R.; Mahadevan, A.; Cravatt, B.F.; Lichtman, A.H. The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci. 2013, 92, 498-505.
21. Hohmann, A.G. Inhibitors of monoacylglycerol lipase as novel analgesics. Br. J. Pharmacol. 2007, 150, 673-675.
22. Dossou, K.S.; Devkota, K.P.; Morton, C.; Egan, J.M.; Lu, G.; Beutler, J.A.; Moaddel, R. Identification of CB1/CB2 ligands from Zanthoxylum bungeanum. J. Nat. Prod. 2013, 76, 2060-2064.
23. Gertsch, J.; Leonti, M.; Raduner, S.; Racz, I.; Chen, J.Z.; Xie, X.Q.; Altmann, K.H.; Karsak, M.; Zimmer, A. β-Caryophyllene is a dietary cannabinoid. Proc. Natl. Acad. Sci. USA 2008, 105, 9099-9104.
24. King, A.R.; Dotsey, E.Y.; Lodola, A.; Jung, K.M.; Ghomian, A.; Qiu, Y.; Fu, J.; Mor, M.; Piomelli, D. Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem. Biol. 2009, 6, 1045-1052.
25. Dutra, R.C.; Simao da Silva, K.A.; Bento, A.F.; Marcon, R.; Paszcuk, A.F.; Meotti, F.C.; Pianowski, L.F.; Calixto, J.B. Euphol, a tetracyclic triterpene produces antinociceptive effects in inflammatory and neuropathic pain: The involvement of cannabinoid system. Neuropharmacology 2012, 63, 593-605.
26. Rani Sagar, D.; Burston, J.J.; Woodhams, S.G.; Chapman, V. Dynamic changes to the endocannabinoid system in models of chronic pain. Philos. Trans. R. Soc. Lond. B 2012, 367, 3300-3311.
27. Shields, S.D.; Eckert, W.A., III; Basbaum, A.I. Spared nerve injury model of neuropathic pain in the mouse: A behavioral and anatomic analysis. J. Pain 2003, 4, 465-470.
28. Thaler, A.; Gupta, A.; Cohen, S.P. Cannabinoids for pain management. Adv. Psychosom. Med. 2011, 30, 125-138.
29. Rahn, E.J.; Hohmann, A.G. Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside. Neurotherapeutics 2009, 6, 713-737.
30. Ashton, J.C.; Milligan, E.D. Cannabinoids for the treatment of neuropathic pain: Clinical evidence. Curr. Opin. Investig. Drugs 2008, 9, 65-75.
31. Campbell, F.A.; Tramer, M.R.; Carroll, D.; Reynolds, D.J.; Moore, R.A.; McQuay, H.J. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001, 323, 13-16.
32. Cunha, T.M.; Verri, W.A., Jr.; Silva, J.S.; Poole, S.; Cunha, F.Q.; Ferreira, S.H. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc. Natl. Acad. Sci. USA 2005, 102, 1755-1760.
33. Guindon, J.; Hohmann, A.G. Cannabinoid CB2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain. Br. J. Pharmacol. 2008, 153, 319-334.
34. Baron, R.; Binder, A.; Wasner, G. Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010, 9, 807-819.
35. Bourquin, A.F.; Suveges, M.; Pertin, M.; Gilliard, N.; Sardy, S.; Davison, A.C.; Spahn, D.R.; Decosterd, I. Assessment and analysis of mechanical allodynia-like behavior induced by spared nerve injury (SNI) in the mouse. Pain 2006, 122, 14. e11-14. e14.